Evaluation of a Novel Point-of-Care Diagnostic Test for Human Papillomavirus (HPV)

Launched by M.D. ANDERSON CANCER CENTER · May 23, 2024

Keywords

ClinConnect Summary

This clinical trial is studying a new type of test for Human Papillomavirus (HPV) to see if it can provide results that are just as accurate as the standard HPV tests we currently use. Researchers hope that these new tests, which are designed to be simpler and require less equipment, can make HPV testing more accessible for women. The trial is currently looking for female participants aged 21 and older who are scheduled to have HPV testing at specific locations, such as MD Anderson and LBJ Hospital.

To participate, women must be able to give their consent and understand the study in English or Spanish. It’s important to note that pregnant women and those who decide against HPV testing will not be included in the study. Participants can expect to undergo the HPV testing as part of their routine care, and by joining this trial, they may help pave the way for more convenient testing options in the future.

Gender

FEMALE

Eligibility criteria

• Inclusion Criteria:
• • 1. People with a cervix 21 years of age or older.
• • 2. Scheduled to undergo hrHPV testing at MD Anderson and The Harris Health System (LBJ Hospital) according to national and institutional guidelines at time of enrollment OR are anticipated to undergo a LEEP, ECC, or biopsy.
• • 3. Willing and able to provide informed consent.
• • 4. Able to perform protocol-required activities. Able to speak and read English or Spanish.
• • Exclusion Criteria
• • 1. Patient or provider decision not to perform HPV testing. This does not apply to patients that are undergoing either a LEEP, ECC or biopsy.
• • 2. Participant or provider decision not to collect a sample for this study.
• • 3. Participants that are pregnant.